Neuropsychiatric complications of chronic kidney disease

Nature Reviews Nephrology

Volumn 6, Issue 8, 2010, Pages 471-479

  McQuillan, Rory ^a   Jassal, Sarbjit V ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CEPHALOSPORIN; GANCICLOVIR; MORPHINE; VALACICLOVIR;

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DELIRIUM; DEPRESSION; DISEASE COURSE; EARLY INTERVENTION; HOSPITALIZATION; HUMAN; MENTAL DISEASE; MORTALITY; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOMETRY; REVIEW; COGNITION; COMPLICATION; INCIDENCE; KIDNEY FAILURE, CHRONIC; MENTAL DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; SURVIVAL RATE;

COGNITION; DISEASE PROGRESSION; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MENTAL DISORDERS; RISK FACTORS; SURVIVAL RATE;

EID: 77955089723     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.83     Document Type: Review

References (103)

1. Addison, T. On the disorders of the brain connected with diseased kidneys. Guy's Hosp. Rep. 4, 1-9 (1839).
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (text revision) (American Psychiatric Association, washington DC, 2010).
3. Rakowski, D. A., Caillard, S., Agodoa L. Y. & Abbott K. C. Dementia as a predictor of mortality in dialysis patients. Clin. J. Am. Soc. Nephrol. 1, 1000-1005 (2006).
4. Murray, A. M. et al. Cognitive impairment in hemodialysis patients is common. Neurology 67, 216-223 (2006).
5. Kurella, T. M. et al. Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am. J. Kidney Dis. 52, 227-234 (2008).
6. Seliger, S. L. et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J. Am. Soc. Nephrol. 15, 1904-1911 (2004).
7. Kurella, M. et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol. 16, 2127-2133 (2005).
8. Buchman, A. S. et al. Kidney function is associated with the rate of cognitive decline in the elderly. Neurology 73, 920-927 (2009).
9. Weiner, D. E. et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am. J. Kidney Dis. 53, 438-447 (2009).
10. Seliger, S. L., Gillen, D. L., Longstreth, W. T. Jr, Kestenbaum, B. & Stehman-Breen, C. O. Elevated risk of stroke among patients with end- stage renal disease. Kidney Int. 64, 603-609 (2003). (Pubitemid 36871932)
11. Khatri, M. et al. CKD associates with cognitive decline. J. Am. Soc. Nephrol. 20, 2427-2432 (2009).
12. Sozio, S. M. et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOiCE) study. Am. J. Kidney Dis. 54, 468-477 (2009).
13. Barzilay, J. i. et al. insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch. Intern. Med. 167, 635-641 (2007).
14. Weiner, D. E. et al. inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int. 73, 1406-1412 (2008).
15. Kim, C. D. et al. High prevalence of leukoaraiosis in cerebral magnetic resonance images of patients on peritoneal dialysis. Am. J. Kidney Dis. 50, 98-107 (2007).
16. irie, F. et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE e4: the Cardiovascular Health Study Cognition Study. Arch. Neurol. 65, 89-93 (2008).
17. Elias, M. F. et al. Chronic kidney disease, creatinine and cognitive functioning. Nephrol. Dial. Transplant. 24, 2446-2452 (2009).
18. Shah, R. C. et al. Relation of blood pressure to risk of incident Alzheimer's disease and change in global cognitive function in older persons. Neuroepidemiology 26, 30-36 (2006).
19. Atti, A. R. et al. Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol. Aging 27, 278-284 (2006).
20. Beard, C. M., Kokmen, E., O'Brien, P C., Ania, B. J. & Melton, L. J. 3rd Risk of Alzheimers disease among elderly patients with anemia: population?based investigations in Olmsted County, Minnesota. Ann. Epidemiol. 7, 219224 (1997).
21. Ania, B. J. & Melton, L. J. 3rd. Risk of Alzheimer's disease among elderly patients with anemia: population-based investigations in Olmsted County, Minnesota. Ann. Epidemiol. 7, 219-224 (1997).
22. Rabie, T. & Marti, H. H. Brain protection by erythropoietin: a manifold task. Physiology (Bethesda) 23, 263-274 (2008).
23. Cerami, A., Brines, M. L., Ghezzi, P & Cerami, C. J. Effects of epoetin alpha on the central nervous system. Semin. Oncol. 28 (Suppl. 8), 66-70 (2001).
24. Erbayraktar, S. et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl Acad. Sci. USA 100, 6741-6746 (2003).
25. Leist, M. et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305, 239-242 (2004).
26. Zhang, Y. et al. Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit. Brain Res. 1294, 153-164 (2009).
27. Temple, R. M., Langan, S. J., Deary, i. J. & Winney, R. J. Recombinant erythropoietin improves cognitive function in chronic hemodialysis patients. Nephrol. Dial. Transplant. 7, 240-245 (1992).
28. Pickett, J. L., Theberge, D. C., Brown, W. S., Schweitzer, S. U. & Nissenson, A. R. Normalizing hematocrit in dialysis patients improves brain function. Am. J. Kidney Dis. 33, 1122-1130 (1999).
29. Brines, M. L. et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. USA 97, 10526-10531 (2000).
30. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).
31. Drueke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084 (2006).
32. Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006).
33. Goldstein, D. A. & Massry, S. G. Parathyroid hormone, uremia, and the nervous system. Contrib. Nephrol. 20, 73-83 (1980).
34. Goldstein, D. A. & Massry, S. G. Effect of parathyroid hormone administration and its withdrawal on brain calcium and electroencephalogram. Miner. Electrol. Metab. 1, 84-91 (1978).
35. Chou, F. F., Chen, J. B., Hsieh, K. C. & Liou, C. W. Cognitive changes after parathyroidectomy in patients with secondary hyperparathyroidism. Surgery 143, 526-532 (2008).
36. Guisado, R., Arieff, A. i., Massry, S. G., Lazarowitz, V. & Kerian, A. Changes in the electroencephalogram in acute uremia. Effects of parathyroid hormone and brain electrolytes. J. Clin. Invest. 55, 738-745 (1975).
37. Cogan, M. G. et al. Central nervous system manifestations of hyperparathyroidism. Am. J. Med. 65, 963-970 (1978).
38. Goldstein, D. A., Feinstein, E. i., Chui, L. A., Pattabhiraman, R. & Massry, S. G. The relationship between the abnormalities in electroencephalogram and blood levels of parathyroid hormone in dialysis patients. J. Clin. Endocrinol. Metab. 51, 130-134 (1980).
39. Teschan, P. E., Bourne, J. R., Reed, R. B. & Ward, J. W. Electrophysiological and neurobehavioral responses to therapy: The National Cooperative Dialysis Study. Kidney Int. 23 (Suppl. 13), S58-S65 (1983).
40. Murray, A. M., Pederson, S. D., Tupper, D. L., Qui, Y. & Collins, A. J. The incidence and progression of cognitive impairment in hemodialysis patients [abstract]. J. Am. Soc. Nephrol. 17, 419A (2006).
41. Murray, A. M. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv. Chronic Kidney Dis. 15, 123-132 (2008).
42. Prohovnik, i. et al. Cerebrovascular effects of hemodialysis in chronic kidney disease. J. Cereb. Blood Flow Metab. 27, 1861-1869 (2007).
43. Toyoda, K. et al. Stroke in patients on maintenance hemodialysis: a 22-year single- center study. Am. J. Kidney Dis. 45, 1058-1066 (2005)
44. Patel, N., Dalal, P & Panesar, M. Dialysis disequilibrium syndrome: a narrative review. Semin. Dial. 21, 493-498 (2008).
45. Chen, C. L. et al. A preliminary report of brain edema in patients with uremia at first hemodialysis: evaluation by diffusion-weighted MR imaging. AJNR Am. J. Neuroradiol. 28, 68-71 (2007).
46. Hill, M. B. Dialysis disequilibrium syndrome. Nephrol. Nurs. J. 28, 348-349 (2001).
47. Murray, A. M. et al. Acute variation in cognitive function in hemodialysis patients: a cohort study with repeated measures. Am. J. Kidney Dis. 50, 270-278 (2007).
48. Jassal, S. V., Roscoe, J., LeBlanc, D., Devins, G. M. & Rourke, S. Differential impairment of psychomotor efficiency and processing speed in patients with chronic kidney disease. Int. Urol. Nephrol. 40, 849-854 (2008).
49. Vos, P F. et al. Effect of short daily home haemodialysis on quality of life, cognitive functioning and the electroencephalogram. Nephrol. Dial. Transplant. 21, 2529-2535 (2006)
50. Churchill, D. N. et al. Effect of high-flux hemodialysis on quality of life and neuropsychological function in chronic hemodialysis patients. Am. J. Nephrol. 12, 412-418 (1992).
51. Suri, R. S. et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int. 71, 349-359 (2007).
52. Tilki, H. E., Akpolat, T., Tunali, G., Kara, A. & Onar, M. K. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on P300 cognitive potentials in uraemic patients. Ups. J. Med. Sci. 109, 43-48 (2004).
53. Buoncristiani, U. et al. Better preservation of cognitive faculty in continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 13 (Suppl. 2), S202-S205 (1993).
54. United States Renal Data System Annual Data Report 2008 [online], http://www.usrds.org (2008).
55. Holroyd?Leduc, J. M., Khandwala, F. & Sink, K. M. How can delirium best be prevented and managed in older patients in hospital? CMAJ 182, 465470 (2010).
56. Sink, K. M. How can delirium best be prevented and managed in older patients in hospital? CMAJ 182, 465-470 (2010).
57. Saxena, S. & Lawley, D. Delirium in the elderly: a clinical review. Postgrad. Med. J. 85, 405-413 (2009).
58. Silva, T. J., Jerussalmy, C. S., Farfel, J. M., Curiati, J. A. & Jacob-Filho, W. Predictors of in- hospital mortality among older patients. Clinics (Sao Paulo) 64, 613-618 (2009).
59. Goncalves, F. Morphine toxicity in renal failure. J. Opioid Manag. 2, 174-176 (2006).
60. Dean, M. Opioids in renal failure and dialysis patients. J. Pain Symptom Manage. 28, 497-504 (2004).
61. Mercadante, S. & Arcuri, E. Opioids and renal function. J. Pain 5, 2-19 (2004).
62. Lotsch, J. Opioid metabolites. J. Pain Symptom Manage. 29, S10-S24 (2005).
63. Hung., T. Y., Seow, V. K., Chong, C. F., Wang, T. L. & Chen, C. C. Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. Emerg. Med. J. 25, 178-179 (2008).
64. Asahi, T. et al. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur. J. Neurol. 16, 457-460 (2009).
65. ishiwata, Y., Son, K., itoga, Y. & Yasuhara, M. Effects of acute renal failure and ganciclovir on the pharmacodynamics of levofloxacin-induced seizures in rats. Biol. Pharm. Bull. 30, 745-750 (2007).
66. Almond, M. K. Aciclovir and valaciclovir neurotoxicity in patients with renal failure. Nephrol. Dial. Transplant. 18, 2680-2681 (2003).
67. Laskin, O. L. et al. Acyclovir kinetics in end- stage renal disease. Clin. Pharmacol. Ther. 31, 594-601 (1982).
68. Grill, M. F. & Maganti, R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann. Pharmacother. 42, 1843-1850 (2008).
69. Garces, E. O. et al. Renal failure is a risk factor for cefepime-induced encephalopathy. J. Nephrol. 21, 526-534 (2008).
70. Sonck, J., Laureys, G. & Verbeelen, D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol. Dial. Transplant. 23, 966-970 (2008).
71. inouye, S. K. Delirium in older persons. N. Engl. J. Med. 354, 1157-1165 (2006).
72. Hedayati, S. S., Minhajuddin, A. T., Toto, R. D., Morris, D. W. & Rush, A. J. Validation of depression screening scales in patients with CKD. Am. J. Kidney Dis. 54, 433-439 (2009).
73. Hedayati, S. S., Minhajuddin, A. T., Toto, R. D., Morris, D. W. & Rush, A. J. Prevalence of major depressive episode in CKD. Am. J. Kidney Dis. 54, 424-432 (2009).
74. Hedayati, S. S. et al. Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int. 74, 930-936 (2008).
75. Hedayati, S. S., Bosworth, H. B., Kuchibhatla, M., Kimmel, P. L. & Szczech, L. A. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int. 69, 1662-1668 (2006).
76. Watnick, S., Wang, P. L., Demadura, T. & Ganzini, L. Validation of 2 depression screening tools in dialysis patients. Am. J. Kidney Dis. 46, 919-924 (2005).
77. Watnick, S., Kirwin, P, Mahnensmith, R. & Concato, J. The prevalence and treatment of depression among patients starting dialysis. Am. J. Kidney Dis. 41, 105-110 (2003). (Pubitemid 36043357)
78. Wuerth, D. et al. identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am. J. Kidney Dis. 37, 1011-1017 (2001).
79. Kimmel, P L. et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int. 57, 2093-2098 (2000).
80. Kessler, R. C. et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105 (2003).
81. Frasure-Smith, N., Lesperance, F. & Talajic, M. Depression following myocardial infarction. impact on 6-month survival. JAMA 270, 1819-1825 (1993).
82. Jiang, W. et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch. Intern. Med. 161, 1849-1856 (2001).
83. Lopes, A. A. et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int. 62, 199-207 (2002).
84. Kimmel, P L. Depression as a mortality risk factor in hemodialysis patients. Int. J. Artif. Organs 15, 697-700 (1992).
85. and practice patterns in the DOPPS. Kidney Int. 64, 254-262 (2003).
86. Kurella, M., Kimmel, P L., Young, B. S. & Chertow, G. M. Suicide in the United States end- stage renal disease program. J. Am. Soc. Nephrol. 16, 774-781 (2005).
87. Misono, S., Weiss, N. S., Fann, J. R., Redman, M. & Yueh, B. incidence of suicide in persons with cancer. J. Clin. Oncol. 26, 4731-4738 (2008).
88. Miller, M. et al. Suicide among US veterans: a prospective study of 500,000 middle-aged and elderly men. Am. J. Epidemiol. 170, 494-500 (2009).
89. Afsar, B. & Akman, B. Depression and nonadherence are closely related in dialysis patients. Kidney Int. 76, 679-680 (2009).
90. Cukor, D., Rosenthal, D. S., Jindal, R. M., Brown, C. D. & Kimmel, P. L. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int. 75, 1223-1229 (2009).
91. Troidle, L. et al. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am. J. Kidney Dis. 42, 350-354 (2003).
92. Koo, J. R. et al. Association of depression with malnutrition in chronic hemodialysis patients. Am. J. Kidney Dis. 41, 1037-1042 (2003).
93. Stenvinkel, P, Barany, P, Heimburger, O., Pecoits-Filho, R. & Lindholm, B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int. Suppl. 80, 103-108 (2002).
94. Tyring, S. et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase iii trial. Lancet 367, 29-35 (2006).
95. Miller, A. H., Maletic, V. & Raison, C. L. inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732-741 (2009).
96. Serebruany, V. L. et al. Enhanced platelet/ endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul. Fibrinolysis 14, 563-567 (2003).
97. Serebruany, V. L. et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 108, 939-944 (2003).
98. Wuerth, D., Finkelstein, S. H. & Finkelstein, F. O. The identification and treatment of depression in patients maintained on dialysis. Semin. Dial. 18, 142-146 (2005).
99. Levy, N. B. et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen. Hosp. Psychiatry 18, 8-13 (1996).
100. Duarte, P S., Miyazaki, M. C., Blay, S. L. & Sesso, R. Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. Kidney Int. 76, 414-421 (2009).
101. Kurella, M., Yaffe, K., Shlipak, M. G., Wenger, N. K. & Chertow, G. M. Chronic kidney disease and cognitive impairment in menopausal women. Am. J. Kidney Dis. 45, 66-76 (2005).
102. Hailpern, S. M., Melamed, M. L., Cohen, H. W. & Hostetter, T. H. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES iii). J. Am. Soc. Nephrol. 18, 2205-2213 (2007).
103. Weiner, D. E. et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am. J. Kidney Dis. 53, 438-447 (2009).